EG 427’s Clinical Data Showing Sustained Incontinence Episode Reduction with EG110A DNA Therapy Maintained at 6 Months Timepoint

January 06, 2026
  • 88% reduction in urinary incontinence episodes in patients with neurogenic bladder sustained through 24 weeks
  • Good tolerability maintained
  • Enrollment and dosing of Cohort 2 in progress
  • Results demonstrate the ability to modulate very specifically the activity of subset of neurons and hence validate EG 427’s HERMES nrHSV-1 technology platform 

Read the full press release.

< back

Recent posts

×

By clicking Consent, you accept the saving of all cookie data on your device. If you click Denied, only the data necessary for the website to function is saved. More information about cookies in the privacy policy.

settings Reject I agree
×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.